Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
Pembrolizumab offered similar efficacy as 2L and ≥3L therapy in advanced UC, supporting use beyond second-line settings. In addition, metastasis, specifically distant metastasis and liver involvement, predicted poorer OS of advanced UC patients under pembrolizumab. These findings support more informed patient selection and treatment sequencing in real-world care.
Authors
- Junki Harada (ORCID: https://orcid.org/0000-0003-0721-7870)
- Yasuyoshi Miyata (ORCID: https://orcid.org/0000-0001-6272-6657)
- Hiroki Kurata
- Kensuke Mitsunari (ORCID: https://orcid.org/0000-0002-6963-5632)
- ITSUHO ITOH
- RYOICHI IMAMURA
- Tsuyoshi Matsuda (ORCID: https://orcid.org/0000-0001-8914-8236)
- Tomohiro Matsuo (ORCID: https://orcid.org/0000-0002-9508-0319)
- Hidenori Itoh
- Tsubasa Kondo
- Akihiro Asai
- S Sakai
Institutions
- Japanese Red Cross Society, Japan (JP)
- Nagasaki Medical Center (JP)
- Japan Community Healthcare Organization (JP)
- National Hospital Organization (JP)
- Ureshino Medical Center (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-05-27
- DOI
- https://doi.org/10.21873/anticanres.17628
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01